[Efficacy and safety of long-acting gonadotropin-releasing hormone analogue in the treatment for metastatic prostate cancer].

Li NC, Song Y, Jiang HW, Ding Q, Gan WD, Guo HQ, Sun ZY, Hu ZQ, Ye ZQ, Wei Q, Na YQ

Zhonghua wai ke za zhi [Chinese journal of surgery]1 Nov 2008

PMID19094763PepBankPUB-19094763

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, triptorelin 11.25 mg reduced total PSA from baseline during treatment.
In plain wordsIn metastatic prostate cancer, triptorelin 11.25 mg lowered PSA compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTotal PSA trajectory, long-acting formulation
Study
n = 65
Comparator
Baseline
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg once · 3 monthsAs given in this study (human).
Measurements
Median TPSA
164.55 microg/L
baseline, 11.25 mg
Median TPSA
11.34 microg/L
day 30, 11.25 mg
Median TPSA
4.12 microg/L
day 60, 11.25 mg
Median TPSA
3.89 microg/L
day 90, 11.25 mg
Source sentences
Summary
At 30, 60 and 90 days, TPSA (median level) declined from 164.55 microg/L into 11.34, 4.12, 3.89 microg/L in 11.25 mg group, and from 101.38 microg/L into 6.88, 2.41, 2.57 microg/L in control group respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
After 3 months treatment, total PSA level decreased significantly from baseline both in 11.25 mg group and 3.75 mg group.
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476301
02HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, triptorelin 3.75 mg reduced total PSA from baseline during treatment.
In plain wordsIn metastatic prostate cancer, triptorelin 3.75 mg lowered PSA compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTotal PSA trajectory, monthly formulation
Study
n = 62
Comparator
Baseline
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg every 28 days, three injections · 3 monthsAs given in this study (human).
Measurements
Median TPSA
101.38 microg/L
baseline, 3.75 mg
Median TPSA
6.88 microg/L
day 30, 3.75 mg
Median TPSA
2.41 microg/L
day 60, 3.75 mg
Median TPSA
2.57 microg/L
day 90, 3.75 mg
Source sentences
Summary
At 30, 60 and 90 days, TPSA (median level) declined from 164.55 microg/L into 11.34, 4.12, 3.89 microg/L in 11.25 mg group, and from 101.38 microg/L into 6.88, 2.41, 2.57 microg/L in control group respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
After 3 months treatment, total PSA level decreased significantly from baseline both in 11.25 mg group and 3.75 mg group.
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476302
03HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, 78.6% of patients receiving triptorelin 11.25 mg had over 90% PSA reduction.
In plain wordsIn metastatic prostate cancer, 78.6% receiving triptorelin 11.25 mg had PSA reductions greater than 90%.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedPSA response, long-acting formulation
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg once · 3 monthsAs given in this study (human).
Measurements
PSA response
78.6%
11.25 mg, over 90% PSA decrease
Source sentences
Summary
The patients ratio with over 90% decreasing from TPSA baseline were 78.6% and 75.5% respectively in two groups (P = 0.700).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476303
04HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, 75.5% of patients receiving triptorelin 3.75 mg had over 90% PSA reduction.
In plain wordsIn metastatic prostate cancer, 75.5% receiving triptorelin 3.75 mg had PSA reductions greater than 90%.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedPSA response, monthly formulation
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg every 28 days, three injections · 3 monthsAs given in this study (human).
Measurements
PSA response
75.5%
3.75 mg, over 90% PSA decrease
Source sentences
Summary
The patients ratio with over 90% decreasing from TPSA baseline were 78.6% and 75.5% respectively in two groups (P = 0.700).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476304
05HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, triptorelin 11.25 mg significantly reduced prostate volume from baseline.
In plain wordsIn metastatic prostate cancer, triptorelin 11.25 mg reduced prostate volume compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseProstate volume, long-acting formulation
Study
n: not reported in source
Comparator
Baseline
Outcome group
Tumor growth · Cancer
Studied dose
11.25 mg once · 3 monthsAs given in this study (human).
Measurements
Median prostate volume
48 mm(3)
baseline, 11.25 mg
Median prostate volume
21.5 mm(3)
after treatment, 11.25 mg
Source sentences
Summary
Prostate volume were also decreased significantly in both groups, median volume declined from 48.0 mm(3) into 21.5 mm(3) in 11.25 mg group and from 45.0 mm(3) into 21.0 mm(3) in 3.75 mg group.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476305
06HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, triptorelin 3.75 mg significantly reduced prostate volume from baseline.
In plain wordsIn metastatic prostate cancer, triptorelin 3.75 mg reduced prostate volume compared with baseline.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseProstate volume, monthly formulation
Study
n: not reported in source
Comparator
Baseline
Outcome group
Tumor growth · Cancer
Studied dose
3.75 mg every 28 days, three injections · 3 monthsAs given in this study (human).
Measurements
Median prostate volume
45 mm(3)
baseline, 3.75 mg
Median prostate volume
21 mm(3)
after treatment, 3.75 mg
Source sentences
Summary
Prostate volume were also decreased significantly in both groups, median volume declined from 48.0 mm(3) into 21.5 mm(3) in 11.25 mg group and from 45.0 mm(3) into 21.0 mm(3) in 3.75 mg group.
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476306
07HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, triptorelin 11.25 mg induced castration-level testosterone of 0.31 microg/L.
In plain wordsIn metastatic prostate cancer, triptorelin 11.25 mg lowered testosterone to castration levels.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTestosterone castration level, long-acting formulation
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
11.25 mg once · 3 monthsAs given in this study (human).
Measurements
Testosterone
0.31 microg/L
11.25 mg
Source sentences
Summary
Both formulations were able to induce castration levels, 0.31 microg/L in 11.25 mg group and 0.26 microg/L in 3.75 mg group (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476307
08HumanRandomized controlled trialEfficacy outcome
In metastatic prostate cancer, triptorelin 3.75 mg induced castration-level testosterone of 0.26 microg/L.
In plain wordsIn metastatic prostate cancer, triptorelin 3.75 mg lowered testosterone to castration levels.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseTestosterone castration level, monthly formulation
Study
n: not reported in source
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg every 28 days, three injections · 3 monthsAs given in this study (human).
Measurements
Testosterone
0.26 microg/L
3.75 mg
Source sentences
Summary
Both formulations were able to induce castration levels, 0.31 microg/L in 11.25 mg group and 0.26 microg/L in 3.75 mg group (P > 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476308
09HumanRandomized controlled trialSafety outcome
In metastatic prostate cancer, adverse events occurred in 13.8% of patients receiving triptorelin 11.25 mg.
In plain wordsIn metastatic prostate cancer, 13.8% receiving triptorelin 11.25 mg had adverse events.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedAdverse events, long-acting formulation
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
11.25 mg once · 3 monthsAs given in this study (human).
Measurements
Adverse events
13.8%
11.25 mg
Source sentences
Summary
13.8% and 17.7% of adverse events were recorded respectively in two groups, and no differences were found (P = 0.547).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476309
10HumanRandomized controlled trialSafety outcome
In metastatic prostate cancer, adverse events occurred in 17.7% of patients receiving triptorelin 3.75 mg.
In plain wordsIn metastatic prostate cancer, 17.7% receiving triptorelin 3.75 mg had adverse events.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedAdverse events, monthly formulation
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
3.75 mg every 28 days, three injections · 3 monthsAs given in this study (human).
Measurements
Adverse events
17.7%
3.75 mg
Source sentences
Summary
13.8% and 17.7% of adverse events were recorded respectively in two groups, and no differences were found (P = 0.547).
1 context sentence(design, population, supporting numbers)
Summary · context
One hundred and twenty-seven patients with documented metastatic prostate cancer were randomized to receive one injection of the 11.25 mg formulation triptorelin (n = 65) or three injections at 28-day intervals of the 3.75 mg formulation (n = 62).
Report a problemFND-1909476310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.